NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allorion Therapeutics

Allorion Therapeutics

Private
Natick, MassachusettsHealthcare & Life Scienceshttps://alloriontx.com/

Last Round

Series B

Mar 9, 2023

Total Funding Raised

$105M

Company Overview

Allorion Therapeutics is a biopharmaceutical company that develops innovative small-molecule drugs aimed at treating cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

allosteric inhibitorsdrug discovery platformbiotechsmall-molecule therapyoncologyprecision medicineautoimmune diseasedrug licensingclinical-stage biotechai drug discoveryin silico drug designpharma partnershipegfr inhibitorcdk2 inhibitorr&d services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allorion Therapeutics Comparables

Compare Allorion Therapeutics with similar companies based on industry and business-model similarity.

Allorion Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avenzo Therapeutics
84%
NiKang Therapeutics
84%
AnHorn Medicines
83%

Allorion Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 9, 2023
Series ANov 24, 2021
AngelJul 1, 2020

Key People

Founding team and executive leadership

Fang Li

Co-Founder Chief Scientific Officer

Founding Team

Qiang Ding

Co-Founder CEO

Founding Team

wen xiong,

COO

Executive Team

Allorion Therapeutics Investors

Notable investors and investment history

Allorion Therapeutics investors
InvestorRounds
Longriver Investment PartnersSeries B
IDG CapitalSeries A
Firstred CapitalSeries A
TF CapitalAngel, Series A, Series B
渶策资本Series B
Elikonventure.comSeries A, Series B
LongRiver InvestmentsSeries B

Allorion Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allorion Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allorion Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNatick, Massachusetts
Employee Range31
Year Founded2020
Last FundingMar 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.